402 related articles for article (PubMed ID: 32511981)
1. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Blay JY; Serrano C; Heinrich MC; Zalcberg J; Bauer S; Gelderblom H; Schöffski P; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Shi K; Ruiz-Soto R; George S; von Mehren M
Lancet Oncol; 2020 Jul; 21(7):923-934. PubMed ID: 32511981
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH; Casbard A; Carucci M; Cox C; Butler R; Alchami F; Madden TA; Bale C; Bezecny P; Joffe J; Moon S; Twelves C; Venkitaraman R; Waters S; Foxley A; Howell SJ
Lancet Oncol; 2020 Mar; 21(3):345-357. PubMed ID: 32035020
[TBL] [Abstract][Full Text] [Related]
4. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
[TBL] [Abstract][Full Text] [Related]
5. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S
Nat Med; 2024 Feb; 30(2):498-506. PubMed ID: 38182785
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
Taniguchi CM; Frakes JM; Aguilera TA; Palta M; Czito B; Bhutani MS; Colbert LE; Abi Jaoude J; Bernard V; Pant S; Tzeng CD; Kim DW; Malafa M; Costello J; Mathew G; Rebueno N; Koay EJ; Das P; Ludmir EB; Katz MHG; Wolff RA; Beddar S; Sawakuchi GO; Moningi S; Slack Tidwell RS; Yuan Y; Thall PF; Beardsley RA; Holmlund J; Herman JM; Hoffe SE
Lancet Oncol; 2023 Dec; 24(12):1387-1398. PubMed ID: 38039992
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Baudin E; Goichot B; Berruti A; Hadoux J; Moalla S; Laboureau S; Nölting S; de la Fouchardière C; Kienitz T; Deutschbein T; Zovato S; Amar L; Haissaguerre M; Timmers H; Niccoli P; Faggiano A; Angokai M; Lamartina L; Luca F; Cosentini D; Hahner S; Beuschlein F; Attard M; Texier M; Fassnacht M; ;
Lancet; 2024 Mar; 403(10431):1061-1070. PubMed ID: 38402886
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.
Israelsen M; Madsen BS; Torp N; Johansen S; Hansen CD; Detlefsen S; Andersen P; Hansen JK; Lindvig KP; Rasmussen DN; Thorhauge KH; Kjærgaard M; Karsdal M; Hansen T; Arumugam M; Trebicka J; Thiele M; Krag A; ;
Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):523-532. PubMed ID: 36893774
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mercuri E; Vilchez JJ; Boespflug-Tanguy O; Zaidman CM; Mah JK; Goemans N; Müller-Felber W; Niks EH; Schara-Schmidt U; Bertini E; Comi GP; Mathews KD; Servais L; Vandenborne K; Johannsen J; Messina S; Spinty S; McAdam L; Selby K; Byrne B; Laverty CG; Carroll K; Zardi G; Cazzaniga S; Coceani N; Bettica P; McDonald CM;
Lancet Neurol; 2024 Apr; 23(4):393-403. PubMed ID: 38508835
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Tawil R; Wagner KR; Hamel JI; Leung DG; Statland JM; Wang LH; Genge A; Sacconi S; Lochmüller H; Reyes-Leiva D; Diaz-Manera J; Alonso-Perez J; Muelas N; Vilchez JJ; Pestronk A; Gibson S; Goyal NA; Hayward LJ; Johnson N; LoRusso S; Freimer M; Shieh PB; Subramony SH; van Engelen B; Kools J; Leinhard OD; Widholm P; Morabito C; Moxham CM; Cadavid D; Mellion ML; Odueyungbo A; Tracewell WG; Accorsi A; Ronco L; Gould RJ; Shoskes J; Rojas LA; Jiang JG
Lancet Neurol; 2024 May; 23(5):477-486. PubMed ID: 38631764
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
Riedel RF; Ballman KV; Lu Y; Attia S; Loggers ET; Ganjoo KN; Livingston MB; Chow W; Wright J; Ward JH; Rushing D; Okuno SH; Reed DR; Liebner DA; Keedy VL; Mascarenhas L; Davis LE; Ryan C; Reinke DK; Maki RG
Oncologist; 2020 Nov; 25(11):e1655-e1662. PubMed ID: 32701199
[TBL] [Abstract][Full Text] [Related]
13. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE; Bolejack V; Ryan CW; Ganjoo KN; Loggers ET; Chawla S; Agulnik M; Livingston MB; Reed D; Keedy V; Rushing D; Okuno S; Reinke DK; Riedel RF; Attia S; Mascarenhas L; Maki RG
J Clin Oncol; 2019 Jun; 37(16):1424-1431. PubMed ID: 31013172
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A; Rosanbalm S; Leinonen M; Olanow CW; To D; Bell A; Lee D; Chang J; Dubow J; Dhall R; Burdick D; Parashos S; Feuerstein J; Quinn J; Pahwa R; Afshari M; Ramirez-Zamora A; Chou K; Tarakad A; Luca C; Klos K; Bordelon Y; St Hiliare MH; Shprecher D; Lee S; Dawson TM; Roschke V; Kieburtz K
Lancet Neurol; 2024 Jan; 23(1):37-45. PubMed ID: 38101901
[TBL] [Abstract][Full Text] [Related]
15. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.
Glover M; Smerdon GR; Andreyev HJ; Benton BE; Bothma P; Firth O; Gothard L; Harrison J; Ignatescu M; Laden G; Martin S; Maynard L; McCann D; Penny CEL; Phillips S; Sharp G; Yarnold J
Lancet Oncol; 2016 Feb; 17(2):224-233. PubMed ID: 26703894
[TBL] [Abstract][Full Text] [Related]
16. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H; Bhadri V; Stacchiotti S; Bauer S; Wagner AJ; van de Sande M; Bernthal NM; López Pousa A; Razak AA; Italiano A; Ahmed M; Le Cesne A; Tinoco G; Boye K; Martín-Broto J; Palmerini E; Tafuto S; Pratap S; Powers BC; Reichardt P; Casado Herráez A; Rutkowski P; Tait C; Zarins F; Harrow B; Sharma MG; Ruiz-Soto R; Sherman ML; Blay JY; Tap WD;
Lancet; 2024 May; ():. PubMed ID: 38843860
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J; Xu RH; Qin S; Pan H; Bai Y; Chi Y; Wang L; Bi F; Cheng Y; Liu T; Ma D; Shen L; Ba Y; Liang J; Wang X; Yau TCC; Ma BB; Yeh KH; Lin JK; Kappeler C; Shapiro J; Kalmus J; Li J
J Gastroenterol Hepatol; 2020 Aug; 35(8):1307-1316. PubMed ID: 31900959
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
Campbell MT; Balderrama-Brondani V; Jimenez C; Tamsen G; Marcal LP; Varghese J; Shah AY; Long JP; Zhang M; Ochieng J; Haymaker C; Habra MA
Lancet Oncol; 2024 May; 25(5):649-657. PubMed ID: 38608694
[TBL] [Abstract][Full Text] [Related]
19. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.
Karakas M; Akin I; Burdelski C; Clemmensen P; Grahn H; Jarczak D; Keßler M; Kirchhof P; Landmesser U; Lezius S; Lindner D; Mebazaa A; Nierhaus A; Ocak A; Rottbauer W; Sinning C; Skurk C; Söffker G; Westermann D; Zapf A; Zengin E; Zeller T; Kluge S
Lancet Respir Med; 2022 Mar; 10(3):247-254. PubMed ID: 34895483
[TBL] [Abstract][Full Text] [Related]
20. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
Doi T; Yamamoto N; Ohkubo S
Future Oncol; 2024 Mar; 20(9):507-519. PubMed ID: 38050698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]